Clene (CLNNW) Accounts Payable : $1.65 Mil (As of Mar. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Clene Accounts Payable?

Clene's Accounts Payable for the quarter that ended in Mar. 2024 was $1.65 Mil.

Clene's quarterly Accounts Payable declined from Sep. 2023 ($1.89 Mil) to Dec. 2023 ($1.50 Mil) but then increased from Dec. 2023 ($1.50 Mil) to Mar. 2024 ($1.65 Mil).

Clene's annual Accounts Payable increased from Dec. 2021 ($1.92 Mil) to Dec. 2022 ($3.01 Mil) but then declined from Dec. 2022 ($3.01 Mil) to Dec. 2023 ($1.50 Mil).

Clene Accounts Payable Historical Data

The historical data trend for Clene's Accounts Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Clene Accounts Payable Chart

Clene Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Accounts Payable

0.89

1.12

1.92

3.01

1.50

Clene Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Accounts Payable	Get a 7-Day Free Trial													0.61	0.85	1.89	1.50	1.65

Clene Accounts Payable Calculation

Accounts Payable represents any money that a company owes its suppliers for goods and services purchased on credit and is expected to pay within the next year or operating cycle.

Clene Accounts Payable Related Terms

Thank you for viewing the detailed overview of Clene's Accounts Payable provided by GuruFocus.com. Please click on the following links to see related term pages.

Clene (CLNNW) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Clene Inc (NAS:CLNNW) » Definitions » Accounts Payable

Comparable Companies

Traded in Other Exchanges

CLNN:USA 84C:Germany

Address

6550 South Millrock Drive, Suite G50, Salt Lake City, UT, USA, 84121

Website

https://www.clene.com

Clene Inc is a clinical-stage pharmaceutical company pioneering the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. It is focused on the development of therapeutics for neurodegenerative diseases. Its reportable segments: (1) the development and commercialization of novel clean-surfaced nanotechnology therapeutics (Drugs, and (2) the development and commercialization of dietary supplements (Supplements).